GSK to collaborate with Chinese biotech on COVID-19 vaccineGlaxoSmithKline has announced plans to collaborate with China’s Xiamen Innovex on a potential vaccine to treat the COVID-19 Share XGSK to collaborate with Chinese biotech on COVID-19 vaccinehttps://pharmaphorum.com/news/gsk-to-collaborate-with-chinese-biotech-on-covid-19-vaccine/
GSK eyes nasal polyps use for Nucala after trial successGlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation Share XGSK eyes nasal polyps use for Nucala after trial successhttps://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/
Pharma giants including Novartis collaborate on COVID-19 therapiesA consortium of life sciences companies including pharma giants such as Novartis and Johnson & Johnson, are to Share XPharma giants including Novartis collaborate on COVID-19 therapieshttps://pharmaphorum.com/news/collaborate-covid19-therapies/
The power of crowdsourced R&DDrug R&D is still dogged by attrition, duplication and waste. Chas Bountra, chief scientist & head of the Share XThe power of crowdsourced R&Dhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/crowdsourcing-rd/
Coronavirus to disrupt EU pharma drug launches, analysts warnBig European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according Share XCoronavirus to disrupt EU pharma drug launches, analysts warnhttps://pharmaphorum.com/news/coronavirus-to-disrupt-eu-pharma-drug-launches-analysts-warn/
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmaNICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in Share XNICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/nice-rejects-nhs-funding-sanofi-regenerons-dupixent-in-asthma/
GSK’s Walmsley gets £2.5m pay rise after strong 2019There can’t be many people in the UK who enjoyed a £2.5 million pay rise this year – Share XGSK’s Walmsley gets £2.5m pay rise after strong 2019https://pharmaphorum.com/news/gsks-walmsley-gets-2-5m-pay-rise-after-strong-sales/
Chinese biotech censured for misleading coronavirus drug claimsChina’s BrightGene Bio-Medical Technology has been censured by the Shanghai Stock Exchange for wrongly claiming it is able Share XChinese biotech censured for misleading coronavirus drug claimshttps://pharmaphorum.com/news/chinese-biotech-censured-for-misleading-coronavirus-drug-claims/
Stada expands OTC business with portfolio of GSK drugsGermany’s Stada is to expand its over-the-counter business after agreeing to buy a portfolio of consumer health products Share XStada expands OTC business with portfolio of GSK drugshttps://pharmaphorum.com/news/stada-expands-otc-business-with-portfolio-of-gsk-drugs/
